hit counter
AnaptysBio, Inc. (ANAB) Stock News Sentiment & Price - Sentifly
ANAB - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



AnaptysBio, Inc. (ANAB)

USA
Biotechnology
NASDAQ
ANAB Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ANAB Latest news
GlobeNewsWire
Neutral
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
2021-10-25 16:37

SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the signing of an agreement with Sagard Healthcare Royalty Partners to monetize a portion of AnaptysBio's future JEMPERLI royalties and milestones. AnaptysBio intends to utilize the proceeds of the transaction towards funding of its wholly-owned preclinical and clinical-stage antibody programs.

Benzinga
Neutral
AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis
2021-10-04 15:06

AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized by the presence of sterile pustules.

GlobeNewsWire
Neutral
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
2021-10-02 12:00

SAN DIEGO, Oct. 02, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that week 16 data from the GPP GALLOP Phase 2 trial of imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) therapeutic antibody, was presented at the 2021 European Academy of Dermatology and Venereology (EADV) Congress. The oral presentation, titled “Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial”, was presented by Dr. Johann Gudjonsson, professor of Dermatology at the University of Michigan.

GlobeNewsWire
Neutral
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-09 16:05

SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on Monday September 13, 2021, at 7:00 a.m. ET via: https://journey.ct.events/view/9ece1408-084b-41dd-9e6e-8977a5086047

Pulse2
Positive
AnaptysBio Shares Increase Over 5% Pre-Market: Why It Happened
2021-08-18 08:50

The shares of AnaptysBio, Inc. (Nasdaq: ANAB) increased by over 5% pre-market. This is why it happened.

Benzinga
Positive
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication
2021-08-18 06:59

The FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors that have progressed on or following prior treatment and have no satisfactory alternative treatment options.

GlobeNewsWire
Neutral
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
2021-08-17 16:32

SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) approved a second indication for GSK's JEMPERLI (dostarlimab-gxly) for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

Zacks Investment Research
Positive
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
2021-08-09 19:13

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 86.67% and 8.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
2021-08-09 16:05

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the second quarter ended June 30, 2021 and provided pipeline updates.

GlobeNewsWire
Neutral
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
2021-05-27 16:15

SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 p.m. ET. The conference will be conducted virtually, and the audio presentation will be available via: https://wsw.com/webcast/jeff174/anab/1811646.

Loading more news...